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Under the unmet need of efficient tumor-targeted drugs for oncology, a recombinant version 
of the plant toxin ricin (the modular protein T22-mRTA-H6) was engineered to self-assemble 
as protein-only, CXCR4-targeted nanoparticles. The soluble version of the construct self-
organized as regular 11 nm-planar entities that were highly cytotoxic in cultured CXCR4+ 
cancer cells upon short time exposure, with a determined IC50 in the nanomolar order of 
magnitude. The chemical inhibition of CXCR4 binding sites in exposed cells results in a 
dramatic reduction of the cytotoxic potency, proving the receptor-dependent mechanism of 
cytotoxicity. The insoluble version of T22-mRTA-H6 was, contrarily, moderately active, 
indicating that free, nanostructured protein is the optimal drug form. In animal models of 
acute myeloid leukemia T22-mRTA-H6 nanoparticles showed an impressive and highly 
selective therapeutic effect, dramatically reducing the leukemia cells affectation of clinically 
relevant organs. Functionalized T22-mRTA-H6 nanoparticles are then promising prototypes 
of chemically homogeneous, highly potent anti-tumor nanostructured toxins for precise 




Cancer is a major, growing, and unsolved health problem worldwide, with an incidence of 
454.8 new cases per 100,000 (men and women) per year, and a mortality of 207.9 per 100,000 
men and 145.4 per 100,000 women (US data; https://www.cancer.gov/about-
cancer/understanding/statistics). Only in 2018, 1,735,350 new cancer cases and 609,640 
cancer deaths are projected to occur in the United States.[1] Conventional cancer treatments 
continue to be based on potent small molecular weight chemicals administered systemically. 
Since these drugs are not targeted to cancer cells they do not preferentially accumulate in 
tumor or metastasis. Biodistributed across healthy tissues, they promote severe hepatic and 




development of new and improved drugs, drug nanoconjugates, therapeutic antibodies, 
antibody-drug conjugates, tumor-targeted nanoscale vehicles and tumor-targeted toxins (such 
as immunotoxins) are being designed to gain specificity and potency, with still limited 
therapeutic improvement. [3] The nanoscale size of the drug, potentially reachable by coupling 
to a vehicle, minimizes renal clearance and favors the enhanced permeability and retention 
(EPR) effect. [4] Among the set of tested new drugs, protein toxins emerge as a very appealing 
alternative. [3] Proteins are biocompatible macromolecules, easily produced by recombinant 
DNA technologies, and more than 400 protein species have been already approved for use in 
humans. [5] As versatile molecules, they are suitable for fine tuning through protein fusion 
technologies, to incorporate relevant functions for use as targeted drugs (such as ligands to 
specific cell surface tumoral markers). [6] Engineered versions of natural protein toxins have 
become promising anti-tumor agents. The Corynebacterium diphtheriae toxin fused to 
interleukin-2 (Denileukin diftitox, ONTAK®), is an FDA-approved drug that targets 
leukemia and lymphoma cell types that display IL-2 receptors. [7] The exotoxin A from 
Pseudomonas aeruginosa has been also produced through recombinant methodologies in 
different versions (SS1P, LMB-2, or BL22), which are under clinical trials for the treatment 
of mesothelioma and leukemia. [8, 9] 
Compared to microbial toxins, plant toxins are extremely potent molecules. [3, 10, 11] Many of 
them (such as ricin, saporin, abrin, trichosanthin, bouganin and gelonin) are ribosome 
inactivating proteins (RIPs). Being N-glycosidases, they irreversibly depurinate a single 
adenine residue in the 23S/25S/28S rRNA stem-loop. This action blocks protein translation 
and leads to fast cell death. Ricin, a RIP originally extracted from the seeds of Ricinus 
communis of approximately 65 kDa, consists in two chains linked by a disulfide bond; the 
chain A (RTA) with N-glycosidase enzymatic activity and the chain B (RTB) with lectin 




is estimated to inactivate 1,500-2,000 ribosomes per minute, [13] being very promising as 
highly active cytotoxic protein drug. We have previously identified the peptide T22, an 
efficient ligand of the cell surface marker CXCR4 (a cytokine receptor selectively over-
expressed in metastatic cells of many cancer types, [14-19]), as a targeting agent for the precise 
tumor delivery of protein-only self-assembling nanoparticles. [20, 21] Some of these constructs 
have been built by the controlled oligomerization of proteins with cytotoxic activity, such as 
pro-apoptotic factors, [22] anti-cancer peptides [22] and microbial toxins. [23] In this context, we 
intended to confer CXCR4+ cell-targeted delivery of ricin assembled as protein nanoparticles 
to determine their selectivity in cell internalization and their performance as cytotoxic drugs. 
This has been done through in vivo administration of either soluble CXCR4-targeted protein 
nanoparticles formed by ricin as building blocks or to particular protein-releasing amyloidal 
aggregates formed by CXCR4-targeted ricin, named bacterial inclusion bodies (IBs), [24] that 
might represent a steady source of functional protein for advanced therapies. [25-27] 
 
2. Results 
The recombinant T22-mRTA-H6 (Figure 1 A) was successfully produced in Escherichia coli 
Origami B, purified by His-based one-step affinity chromatography and detected as a single 
protein species with the expected molecular mass of 35.91 kDa (Figure 1 B), that was fully 
confirmed by mass spectrometry (not shown). The pure protein was straightforward observed 
by both, DLS and FESEM, as ~11 nm entities occurring in the storage buffer without further 
treatment (Figure 1 C, D), indicating the spontaneous formation of self-assembled 
nanoparticles. This was the expected outcome as the combination of cationic peptides at the 
amino terminus and polyhistidines at the carboxy terminus has been proved to be optimal to 
promote protein oligomerization as regular nanostructures, [28] irrespective of the core protein 




resulted in monomers of 5.5 nm (Figure 1 C), which represented the probable building blocks 
of the nanoparticles. In the related self-assembling protein T22-GFP-H6, in which the sizes of 
the building block and the assembled version are both equivalent to those of T22-mRTA-H6, 
the use of small-angle X-ray scattering and other sophisticated analytical methods [29] as well 
as in silico modelling [30] have revealed that the nanoparticle was formed by approximately 10 
monomers. Being estimative, this figure fits also to T22-mRTA-H6. The analysis of T22-
mRTA-H6 nanoparticles by circular dichroism (CD) revealed a structural composition in 
which α-helix predominates (29.2 %, Figure 1 E). However, a Thioflavin T (Th T) assay has 
also revealed the occurrence of intermolecular β-sheet interactions (Figure 1 F) that might 
contribute to the stability of protein nanoparticles, and that is also compatible with the extent 
of important β-sheet structure found in the CD (Figure 1 E). Since the nanostructured ricin 
was intended to be delivered in tumoral tissues, we wondered if the nanoparticles could be 
still stable in the abnormal pH values observed in the tumor environment, that have been 
reported to range from approximately 6.3 (intracellular) to 7.4 (extracellular). [31, 32] As 
observed, T22-mRTA-H6 remained fully assembled under these conditions (Figure 1 F), what 
supports the usability of construct from the stability point of view. 
 
Figure 1. Physicochemical properties of T22-mRTA-H6. A. Modular scheme and amino 




material and methods, in which the Asn residue 123 has been replaced by Ala (underlined). 
Sizes of the boxes are only indicative. B. Fractioning between insoluble (I) and soluble (S) 
cell fractions in total cell extracts, revealed by WB, upon protein production at 37 ºC for 3 h. 
SDS-PAGE analysis of T22-mRTA-H6 upon one-step affinity purification, revealed by 
Comassie blue (CB) staining and by Western blot (WB) using an anti-his antibody. U and AB 
stand for Unstained and All Blue markers respectively (Bio-Rad, Refs161-0363 and 161-
0373), and 1, 2 and 3 indicate, respectively, the unspecific elution peak and two peaks with 
increasing level of purity. Protein in peak 3 was used in further experiments. C. 
Hydrodynamic size (and Z potential) of T22-mRTA-H6 nanoparticles formed spontaneously 
upon purification (red line), determined by DLS. Pdi is polydispersion index, and all figures 
indicate nm. The size of the monomer, determined upon disassembling the material with 1 % 
SDS for 40 min, is also indicated (green line). D. FESEM imaging, at different magnifications, 
of T22-mRTA-H6 nanoparticles. Bars represent 20 nm. E. Far UV CD of T22-mRTA-H6 in 
carbonate-bicarbonate buffer at pH 8 measured at 25ºC. F. ThT fluorescence emission spectra 
alone (black line) or in the presence of T22-mRTA-H6 (light grey line) and T22-mRTA-H6 
previously heated at 100ºC (dark grey line).  λex=450 nm. In the plot at the bottom, ThT 
fluorescence emission at 490 nm of T22-mRTA-H6 (black bar) and T22-mRTA-H6 
previously heated at 100ºC (grey bars). G. Size of T22-mRTA-H6 nanoparticles dialyzed 
against 51 mM sodium phosphate, 158.6 mM trehalose dehydrate, 0.01 % polysorbate-20 
buffer at different pH values, determined by DLS.  
 
In order to test the functionality of the recombinant ricin in such assembled form, cultured 
CXCR4+ HeLa cells were exposed to different concentrations of ricin-based nanoparticles. 
These materials showed a potent, dose-dependent cytotoxicity that essentially abolished cell 
viability at 100 nM (Figure 2 A). After 72 h of exposure, the IC50 was determined to be 13 ± 
0.5 nM. To confirm if, as expected, T22-mRTA-H6-mediated cell death was dependent on its 
cell binding and internalization of the protein via the cell surface receptor CXCR4 and its 
ligand T22, we tested if a potent CXCR4 antagonist, AMD3100, [33] could be able to recover 
cell viability when used as a competitor of the toxin, at a molar ratio of 10:1. As observed 
(Figure 2 B), AMD3100 dramatically enhanced cell viability in T22-mRTA-H6-treated cells 
proving a specific, receptor-mediated penetration of the nanoparticles into target cells. To 
further confirm such precision cell entry mechanism, we decided to expose non tumoral 
(CXCR4-) 3T3 cells and representative CXCR4- and CXCR4+ tumoral cell lines to T22-
mRTA-H6, and also to a conventional chemical drug used in the treatment of several cancer 




[34] These cell lines, with different levels of CXCR4 expression (Figure 2 C), supported 
different levels of protein internalization mediated by the specific interaction between T22 
and CXCR4 (Figure 2 D). This was determined through the uptake of T22-GFP-H6, a self-
assembling fluorescent protein closely related to T22-mRTA-H6, that contains the same 
ligand of CXCR4 also accommodated at the amino terminus of the polypeptide. [28] It must be 
noted that as predicted, CXCR4 expression and T22-mediated protein internalization showed 
a parallel behavior (compare Figure 2 C and D). Then, when they were finally comparatively 
tested, , the ricin-based protein nanoparticle promoted specific cell death only in CXCR4+ 
cancer cells but not in normal cells, at a dose (100 nM) at which Ara-C did not show any toxic 
effect on any of these cell lines (Figure 2 E). This observation proved not only the effective 
targeting of the protein drug but also its superior cytotoxicity compared to an equimolar dose 
of the model chemical drug. 
 
Figure 2. Cytotoxicity and CXCR4 specificity of T22-mRTA-H6 nanoparticles. A. 
Viability of cultured CXCR4+ HeLa cells upon 72 h of exposure to T22-mRTA-H6 




cell death in HeLa cells exposed to different concentrations of T22-mRTA-H6 nanoparticles 
for 72 h, mediated by the CXCR4 antagonist AMD3100 (always at an excess molar ratio of 
10:1). C. Levels of CXCR4 membrane protein determined by flow cytometry of different cell 
lines (3T3, MV411, THP1 and HeLa), expressed as mean fluorescence intensity ratio ± SE. D. 
Extent of internalization of 100 nM T22-GFP-H6 in the different cell lines at 1 h of exposure. 
Results are expressed as mean fluorescence intensity ratio ± SE. E. Viability of cultured 
CXCR4- 3T3 cells upon 48 h of exposure to T22-mRTA-H6 nanoparticles and the small 
molecular weight antitumoral drug Ara-C, at different concentrations. The commercial 
CXCR4- and CXCR4+ human AML cell lines (MV411 and THP1 respectively) are included as 
controls. Ara-C showed cytotoxicity above 100 nM (not shown). The standard error is 
represented in all bars. The level of significance is indicated by superscripts (*p<0.05, 
**p<0.01).  
 
At this stage, we wanted to confirm that the cytotoxicity promoted by T22-mRTA-H6 was 
linked to the uptake of the nanoparticles inside CXCR4+ cells, and triggered from within. This 
was reached by exposing HeLa cells to ATTO-labelled nanoparticles and monitoring 
internalization. As observed (Figure 3 A), nanoparticles were internalized by cells at least up 
to 24 h. As expected for an active version of ricin, apoptosis was detected though both 
annexin affinity assay and by Hoechst staining (Figure 3 B), and the number of apoptotic cells 
seemed to peak at around 15-24 h post exposure. In addition, mitochondrial damage was 
confirmed by the significant increase in the number of cells with lowered JC-1 red 
fluorescence at 15 and 24 h after treatment with T22-mRTA-H6 (Figure 3 C), indicative of a 
depolarization in the mitochondrial Ψ linked to apoptotic induction. Interestingly, cell 
damage occurred without a detectable increase in reactive oxygen species (ROS, Figure 3 D), 
while the formation of apoptotic bodies in ricin-exposed HeLa cells was clearly caspase–
dependent (Figure 3 E). The combination of these data indicates that T22-mRTA-H6-









Figure 3. Cell penetrability and intracellular toxicity of T22-mRTA-H6 nanoparticles. A. 
Intracellular fluorescence in cultured HeLa cells exposed to 100 nM of ATTO488 stained 
T22-mRTA-H6. Extracellular fluorescence was fully removed by a hash trypsin treatment as 
described [35]. B. Under the same conditions, the externalized phosphatidylserine was 
detected by Annexin V Detection Kit (APC, eBioscience) in cells exposed to non-stained 
T22-mRTA-H6. Dead cells were spotted with propidium iodide (PI). Quadrant Q1 shows 
HeLa cells marked with PI. Q2 shows cells marked with Annexin V and PI. Q3 shows cells 
without PI nor Annexin V. Q4 shows cells marked with Annexin V. Therefore, dead cells are 
shown in Q1 and Q2 while living cells in Q3 and Q4. Apoptotic cells are shown in Q4. At the 
bottom, Hoechst staining of HeLa cell under the above conditions. Images were obtained by 
fluorescence microscopy (x400). C. Loss of JC-1 Red fluorescence in T22-mRTA-H6-treated 
cells as described above, indicative of a change in the mitochondrial Δψ. D. Levels of cellular 
ROS detected with a fluorescence microplate assay. HeLa cells were treated with either buffer, 
T22-mRTA-H6 (100 nM, for 15 or 24 hours) or 100 µM Pyocyanin (1 hour) as a positive 
control. Values are expressed as relative fluorescence units ± SE. E. Inhibition of caspases 
with zVAD-fmk reverses the antitumor activity of T22-mRTA-H6 in HeLa cells. Cells were 
pretreated for 1 hour with 100 µM zVAD-fmk and then exposed to 100 nM T22-mRTA-H6 
for 48 hours. Cell viability is expressed as the percentage of cell survival compared with the 
control. Values are mean ± SE. Vehicle indicates treatment with buffer. The level of 






The suitable cell-targeting of the nanostructured version of ricin conferred by the peptide T22 
(Figure 2), and the fact that most of the T22-mRTA-H6 protein was obtained in insoluble 
form (Figure 1 B), prompted us to evaluate if the insoluble version of ricin might also exhibit 
cell-targeted cytotoxicity. In this context, we have recently described how the presence of T22 
and other cell ligands, in recombinant proteins that form bacterial IBs, [27] allow an efficient 
and specific cell penetration of the whole protein clusters. In the same conceptual line, 
bacterial IBs formed by self-assembling proteins might contain quasi-native forms of 
nanoparticles or assembling precursors. [36] IB proteins retain functionalities of the soluble 
protein version and can be gradually released from the aggregates when exposed to cells [26] 
or when implanted in vivo by local injection. [25] The ultrastructural morphometry of insoluble 
version of T22-mRTA-H6 was observed in a nearly native state by FESEM as conventional 
IBs, namely pseudo-spherical protein clusters with an average diameter size ranging from 400 
to 600 nm (Figure 4 A).  
When exposing HeLa cells to increasing amounts of T22-mRTA-H6 IBs, a mild cytotoxic 
effect was indeed observed (Figure 4 B), although the differences in cell viability, when 
comparing with untreated cell cultures, were in the limits of significance. In addition, the 
insoluble version of T22-GFP-H6 (forming similar IBs, [27]), a self-assembling CXCR4-
targeted protein devoid of any cytotoxic domain, also promoted a transient and mild reduction 
of cell viability. However, in this case, cells showed an immediate recovery at longer time 
exposures that, in contrast, was not found associated to T22-mRTA-H6. Despite previous data 
about the potential of functional protein release from IBs, [25] the biological effect of T22-






Figure 4. Properties of T22-mRTA-H6 IBs. A. FESEM images of isolated T22-mRTA-H6 
IBs at different magnifications. Bars indicate 1 μm. B. Viability of cultured CXCR4+ HeLa 
cells upon different times of exposure to T22-mRTA-H6 IBs and to control, non-functional 
IBs formed by the related protein T22-GFP-H6. Exposure time is indicated in hours. The 
standard error is represented by a black line. The level of significance is indicated by 
superscripts (* p<0.05). 
 
The antitumor effect of both T22-mRTA-H6 soluble nanoparticles and T22-mRTA-H6 IBs 
was evaluated in a disseminated AML animal model. NSG mice were injected with THP1-
Luci cells to generate leukemia dissemination in mice. Two days after cell injection through 
the vein tail, we performed a single dose injection in the mice hypodermis (SC) of 1 mg of 
T22-mRTA-H6 IBs in two mice (IB-T22mRTA group). In a different mouse group, we 
started daily intravenous administrations of 10 µg of soluble T22-mRTA-H6 (T22mRTA 
group) to one mouse or buffer alone (VEHICLE group) to three mice, for a total of 10 doses. 
No effects on mice weight were observed during the treatments (data not shown). The 
progression and dissemination of leukemia was assessed by monitoring BLI using the IVIS 
Spectrum. From the day 6 and until the end of the experiment, the mouse treated with soluble 
T22-mRTA-H6 (T22mRTA) showed lower luminescence emission than the VEHICLE group 
(Figure 5A). Thus, as measured by BLI, treatment with soluble T22-mRTA-H6 inhibited the 




10 th doses of T22-mRTA-H6 at 10 µg per dose (which corresponded to day 6, 8, 10 or 13 
after injection of cells, respectively). In contrast, no differences in BLI were found between 
mice treated with T22-mRTA-H6 IBs (IB-T22mRTA) and the control VEHICLE mice 
(Figure 5A).  
In a next step, the antitumor activity of nanoparticles was analyzed in affected organs ex vivo 
14 days after the injection of cells when mice presented signs of advanced disease. The 
analyses with the IVIS Spectrum showed that the treatment with soluble T22-mRTA-H6 
nanoparticles (T22mRTA) decreased BLI in the bone marrow (backbone and hindlimbs), liver 
and spleen, in contrast to the findings in mice treated with buffer alone (VEHICLE) (Figure 
5B). However, the treatment with T22-mRTA-H6 IBs (IB-T22mRTA) did not show changes 
in BLI in the same tissues in comparison to control mice (VEHICLE) (Figure 5B).  
In addition, we evaluated the dissemination of leukemic cells in the affected organs of the 
animal by IHC of CD45, a human leukocyte marker that detects AML THP1 cells. Results 
correlated with BLI analyses showing that treatment with soluble T22-mRTA-H6, differently 
from those registered after T22-mRTA-H6 IBs treatment, reduced the dissemination in the 
infiltrated tissues, by detecting lower number of CD45 positive cells in bone marrow, liver 
and spleen in the mouse treated with soluble T22-mRTA-H6 (Figure 5C). Finally, we 
performed H&E staining of the infiltrated organs and additional organs not affected by 
leukemia cells. We did not observe any sign of toxicity in any of the affected or unaffected 
tissues, neither with the soluble T22-mRTA-H6 nor with the T22-mRTA-H6 IBs treatments 







Figure 5. Antitumor activity of T22-mRTA-H6 in a disseminated AML mouse model. A. 
Follow-up of bioluminescence emitted by mice treated with soluble T22-mRTA-H6 
nanoparticles (T22mRTA), T22-mRTA-H6 IBs (IB-T22mRTA) or buffer (VEHICLE) during 
the 14 days of the experiment, analyzed by IVIS Spectrum. B. Levels of luminescence 
detected ex vivo in IVIS Spectrum in the tissues infiltrated with leukemic cells such as 
backbone, hindlimbs, liver and spleen of mice treated with buffer (VEHICLE), T22-mRTA-
H6 IB (IB-T22mRTA) or soluble T22-mRTA-H6 (T22mRTA). C. Detection of CD45 
positive cells by IHQ in spleen, liver and bone marrow of mice treated with buffer 
(VEHICLE), T22-mRTA-H6 IBs (IB-T22mRTA) or soluble T22-mRTA-H6 nanoparticles 
(T22mRTA). T22mRTA, mouse treated with soluble T22-mRTA-H6; IB-T22mRTA, mouse 









Figure 6. Histopathology in the disseminated AML mouse model after a treatment with 
T22-mRTA-H6. Hematoxylin and eosin staining of normal (heart, lung, kidney) and 
leukemia infiltrated organs (bone marrow, liver, spleen). Images were taken in the microscope 
with a 20x objective and an Olympus DP72 digital camera. H&E, Hematoxylin and Eosin; 
T22mRTA, mouse treated with soluble T22-mRTA-H6; IB-T22mRTA, mouse group treated 






Functional recruitment in single chain modular polypeptides is a promising strategy for the 
generation of self-targeted and self-delivered drugs, that are chemically homogenous and 
produced in a single step in recombinant cell factories. [37] Protein drugs represent a big sector 
in the pharmacological market. [5] Their easy industrial biofabrication and scalability 
combined with the intrinsic biocompatibility and functional versatility, approachable by 
genetic engineering, make proteins a very convenient category of tuneable pharmaceuticals. 
[38, 39] In oncology, cytotoxic proteins selected from nature have been engineered and adapted 
to act as anti-tumor agents, by means of different approaches that must necessarily consider 
cell targeting. [3] Immunotoxins are relevant representatives of how protein toxins can be 
targeted by simple fusion technologies in monovalent complexes, with relevant potential for 
precise cell killing. [40-42] However, proper targeting is not regularly achieved in current 
nanomedicine [43] and the amount of cell targeted drugs that reach the intended tumor tissues, 
especially in oncology, is rather limited (usually < 1%). [44] Specifically, immunotoxins have 
not so far fulfilled the requirements regarding a convenient therapeutic index, as side toxicity 
is still relevant. [3] The combination of highly potent toxins with effective targeting is then 
necessary for a highly precise and selective cell killing, that might be still optimized by a 
regular and multivalent display of the targeting agent on the surface of the drug. [45] Also, 
formulating a protein drug within the nanoscale size should favor the enhanced permeability 
and retention effects, [4] minimizing the biological barriers in the drug delivery process. 
Under these premises, we have engineered the highly potent plant toxin ricin as a CXCR4-
targeted, protein-only nanoscale drug with a multivalent presentation of the ligand, the 
peptide T22, reached through the regular self-assembling of ricin as stable 11 nm-




assembles as 12 nm-nanoparticles, has been modelled as oligomerizing in approximately 10 
subunits accommodated in a toroid architecture, thus ensuring a sufficient multivalent display 
of the ligand. [29, 30] According to the similarities in the molecular mass of the building block 
and in the final size of the resulting nanoparticles, T22-mRTA-H6 seems to self-arrange in a 
similar pattern (Figure 1). Ricin has been largely considered as a drug component in cancer 
therapies, [46] and previously explored in form of immunotoxins with moderate efficacy. [47-49] 
In the nanoconstruct generated here, ricin is highly active and fully potent on target cells, 
indicative of that oligomerization is not preventing functionality.  
This particular approach highly increases the selectivity of the cytotoxic potential of ricin 
against CXCR4+ cancer cells because of the combination of three main and critical effects. 
Firstly, the specific uptake of the therapeutic protein was achieved because of the multivalent 
display of the CXCR4 ligand, T22, on the nanoparticle and exclusive CXCR4 receptor 
overexpression in the target cancer cell membranes. This fact prevents internalization and 
toxicity on normal cells with low or negligible levels of CXCR4. Secondly, the avoidance of 
the severe side effects that appeared on previous clinical trials testing ricin anticancer effect 
that led to their discontinuation. [13, 46] Specifically, we incorporated the mutant (N132A) ricin 
A chain as functional building block of the nanoparticle, to suppress the potential vascular 
leak syndrome. We also excluded the use of ricin B-chain to block the severe toxicity 
associated with its non-specific binding to glycoproteins or mannose receptors expressed on 
the membrane of non-tumor cells (e.g. Kupffer cells of the liver sinusoids). Finally, the 
enhanced delivery of the biologically active ricin A chain to the cytosol of target cells (Figure 
3 A) was reached because of the addition of the furin cleavage site that releases the active 
domain from the nanoparticle in the endoplasmic reticulum, and a KDEL sequence which 
allows the translocation of the biologically active toxin to the cytosol, avoiding its lysosomal 




of   multidrug resistance, that mainly relates to drug efflux by cancer cells through the ATP-
binding cassette (ABC) transporters activity, overexpression of ABC transporters associating 
with poor response to therapy. [50] Low molecular weight drugs enter cells by diffusion across 
membranes, which renders them vulnerable to their efflux by ABC transporters. In contrast, 
the nanoscale size of oligomeric ricin is expected to avoid passive diffusion. Entering 
CXCR4+ cells through endocytic vesicles, the protein achieves high intracellular 
concentration in absence of (or reversing) the multidrug resistance phenotype that might have 
been observed for a free small drug. This effect, associated with the entry route, has been 
reported for doxorubicin-loaded polymeric nanoparticles and doxorubicin-polymer conjugates, 
among others. [51-52]  
 The combination of these three crucial effects in basic cellular pathways makes for a 
dramatic increase of ricin A antineoplastic activity. Thus, the previously reported IC50 of 
untargeted ricin A in HeLa cells (IC50 36 µg/ml (1 µM)) [53] is here reduced about 100 fold 
(IC50=13 nM) because of selective CXCR4 cancer cell targeting, KDEL sequence and furin 
site incorporation into the nanoparticle. The reached IC50 (Figure 2) is in the same nM range 
than that described by other highly lethal toxins (such as diphtheria toxin derivatives, [54-56] 
Pesudomonas exotoxin [57] or neurotoxins [58]). However, this engineered version is highly 
promising for the further development of the present prototype as an efficient oncological 
nanostructured drug, since it keeps the full selectivity for the cell surface cytokine receptor 
CXCR4 (Figure 2) while keeping a nanostructured organization with a multivalent 
presentation of the surface receptor (Figure 1). In addition, in a molar basis, T22-mRTA-H6 is 
more cytotoxic on AML CXCR4+ cells than Ara-C (Figure 2 E), a basic chemical drug 
included in most AML treatment protocols. [34] Importantly, the precise cytotoxic activity of 
T22-mRTA-H6 nanoparticles is conserved in vivo after systemic administration, which leads 




marrow, liver and spleen) in the CXCR4+ AML model (Figure 5). These findings were 
associated with absence of any detectable systemic (not shown) or histological toxicity in off-
target organs during the experiment time (Figure 6). It could not be fully excluded that in 
longer treatments ricin (as well as other recombinant toxins or therapeutic fusion proteins) 
may induce an immune response, that if involving antigens shared with endogenous protein 
might lead to adverse effects. [59, 60] However, the modified version of ricin used here avoids 
the vascular leak syndrome (VLS), the major concern in the clinical trial of a ricin A-antibody 
(CD19/CD12) immunotoxin (https://clinicaltrials.gov/ct2/show/NCT01408160). In this 
context, further de-immunization might be feasible, if required, to improve the clinical 
performance of T22-mRTA-H6 or derived drugs, ensuring low immunogenicity and 
avoidance of autoimmune diseases. This could be done by an approach similar to that carried 
out for diphtheria and Pseudomonas aeruginosa toxins. These microbial proteins, components 
of most of third generation immunotoxins under clinical evaluation, are successfully 
engineered by the removal of non-essential sequences and by the genetic elimination of 
antigenic T and B cell epitopes, without compromising their antitumor activity. [60] 
Combining the impressive therapeutic effects observed in vivo and the fact that CXCR4 is a 
tumoral marker relevant in more than 20 human neoplasias, [61] its overexpression correlating 
with aggressiveness, [62-66] T22-mRTA-H6 nanoparticles combine selectivity, cytotoxicity, 
nanoscale size and multivalent display in a chemically homogeneous entity devoid of any 





One of the most potent toxins in nature, ricin, has been genetically instructed to self-assemble 




by using a promising protein engineering toolkit. The resulting nanoscale material has been 
shown as highly cytotoxic and highly selective over CXCR4+ cells, resulting in an unusually 
strong and efficient antitumor activity in a mouse model of the difficult-to-treat disseminated 
acute myeloid leukemia, in complete absence of side-toxicity. This analysis opens a plethora 
of possibilities to combine highly toxic proteins with a highly selective tumor-targeting 
platform, that within the nanoscale, would fulfil the emerging concept of self-assembled, self-
targeted vehicle-free recombinant drugs for precision medicines. 
 
5. Materials and methods 
5.1 Genetic design and protein production  
The recombinant protein T22-mRTA-H6 (Figure 1 A) was designed to include the highly 
specific CXCR4 ligand T22 [20] at the amino terminus followed by a mutated version of the 
ricin A chain, and a hexahistidine tail at the carboxy terminus. The mutation N132A was 
introduced to suppress the vascular leak syndrome in potential future in vivo administrations, 
keeping the cytotoxic activity. In addition, a furin cleave site was also incorporated to allow 
the release of the accessory N-terminal region in the endosome and the intracellular activity of 
ricin in a quasi-native sequence format. A KDEL motif was also incorporated to favour 
endosomal escape. [67] The plasmid construct pET22b-T22-mRTA-H6, encoding the protein 
under the control of the bacteriophage T7 promoter, was generated by GeneArt and 
transformed into Escherichia coli Origami B cells.  
 
5.2 Production and purification of soluble protein  
Recombinant bacteria were cultured in lysogeny broth (LB) medium with 100 µg/ml 
ampicillin, 15 µg/ml kanamycin and 12.5 µg/ml of tetracycline, at 37 ºC and 250 rpm. The 
recombinant gene expression was induced by adding 0.1 mM isopropyl-β-
thiogalactopyronaside (IPTG) when the OD of the culture reached a value between 0.5 and 
0.7. Cultures were subsequently incubated overnight at 20 ºC and 250 rpm. Cells were 
harvested and centrifuged (5,000 g, 15 min, 4 ºC). The cell pellet was resuspended in Wash 




Polysorbate-20, 15 mM imidazole, 300 mM NaCl) in presence of protease inhibitor cocktail 
Complete EDTA-Free (Roche). Bacterial cells were sonicated twice at 10% amplitude and 
once at 15% of amplitude for 10 min each round, centrifuged (15,000 g, 45 min, 4 ºC) and 
soluble fraction purified by affinity chromatography with a HiTrap Chelating HP column in 
an AKTA purifier FPLC, (GE Healthcare). After the samples were filtered (0.22 µm) and 
injected into the column, the fractions to be collected were eluted at approximately 30% 
Elution Buffer (51 mM sodium phosphate, pH=8, 158.6 mM trehalose dihydrate, 0.01% 
Polysorbate-20, 500 mM imidazole, 300 mM NaCl). The buffer exchange was done in 
Centricon Centrifugal Tubes Ultracel 10,000 NMWL. T22-mRTA-H6 was found to be highly 
stable in 51 mM sodium phosphate pH=6.2, 60 mg/ml α-trehalose dehydrate, 0.01% 
polysorbate-20. Protein purity was analyzed by SDS electrophoresis on TGX Stain-Free gels 
(Bio-Rad), followed by Western blotting using an anti-His monoclonal antibody (Santa Cruz 
Biotechnology). Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on 
TGX Stain-Free Gels (Bio-Rad) was conducted to analyze the protein. Samples were diluted 
in denaturing buffer (0.53 M Tris Base, 5.52 M glycerol, 0.27 M SDS, 2.84 M β-
mercaptoethanol, 7.99 M urea) at a 3:1 molar ratio, boiled at 96ºC for 10 min and loaded into 
the gels lanes. For the Western Blot, an anti-His monoclonal antibody was used (Santa Cruz 
Biotechnology) followed by a goat anti mouse IgG (H+L)-HRP secondary antibody (Ref: 
170-6516) conjugate (Bio-Rad, Ref: 170-6516). Images were observed using ChemiDoc 
Touch Imaging System. Protein production has been partially performed by the ICTS 
“NANBIOSIS”, more specifically by the Protein Production Platform of CIBER-BBN/ IBB 
(http://www.nanbiosis.es/unit/u1-protein-production-platform-ppp/) 
 
5.3 Production and purification of insoluble protein  
Recombinant bacteria were cultured in LB at 37ºC and 250 rpm until the OD reached between 
0.5 and 0.7, and gene expression was induced by 1 mM IPTG. Then, cells were further 
incubated to allow gene expression for 3 h at 37 ºC and 250 rpm. After sedimentation (5,000 g, 
15 min, 4 ºC), the pellet was resuspended in 0.22 µm filtered lysis buffer (Tris 1 M pH=8, 
NaCl 4 M, EDTA 50 mM) in presence of protease inhibitor cocktail Complete EDTA-Free 
(Roche), the protease inhibitor phenylmethane sulfonyl fluoride (PMSF, 100 mM) and 50 µg 
lysozyme/ml, followed by an incubation at 37 ºC and 250 rpm for 2 h. Cells were disrupted in 
a French Press (5 rounds at 1,200 psi) and kept at -80 ºC overnight. Samples were thawed and 




after sedimentation (15,000 g, 15 min, 4 ºC), pellets were resuspended in the same volume of 
filtered lysis buffer. The following reagents were then added to the sample: 1 µl MgSO4 (1 
M)/ml cell culture,1 µg DNAse/ml cell culture The culture was then incubated for 1 h at 37 ºC 
and 250 rpm agitation. As a sterility assay, LB plates were seeded with 100 µl of culture at 37 
ºC, overnight, and the suspension of insoluble protein was frozen at -80 ºC overnight. The 
suspension was frozen and thawed daily until no bacterial colonies appeared in the plates. 
Then, after sedimentation (15,000 g, 15 min, 4 ºC), the supernatant was discarded, and each 
pellet was resuspended in filtered ultrapure water and aliquots were made. Finally, after 
sedimentation of insoluble material (15,000 g, 15 min, 4 ºC), supernatants were discarded and 
pellets were stored at -80 ºC.  
 
5.4 Quantitative protein analysis 
Protein purity was analyzed by sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) on a Chemi Doc Touch Imaging System (Bio-Rad). Briefly, both soluble and 
insoluble samples were mixed with in denaturing buffer (0.53M Tris Base, 5.52 M glycerol, 
0.27 M sodium dodecylsulphate (SDS), 2.84 M β-mercaptoethanol, 7.99 M urea) at a ratio 3:1, 
boiled for 5 or 45 min, respectively, and loaded onto the gels. For the Western Blot, an anti-
His monoclonal antibody was used (Santa Cruz Biotechnology) followed by a goat anti mouse 
IgG (H+L)-HRP secondary antibody conjugate (Bio-Rad). Gels were scanned at high 
resolution and bands were quantified with Quantity One Software (Bio-Rad) using a known 
protein standard of soluble recombinant T22-mRTA-H6. 
 
5.5 Quantitative and qualitative analyses of soluble protein  
Protein molecular weight was verified by mass spectrometry (MALDI-TOF), and 
concentration determined by Bradford Assay (Dye Reagent Concentrate Bio-Rad kit). 
Volume size distribution of protein nanoparticles was determined by Dynamic Light 
Scattering (DLS). For that, a 50 μl aliquot (stored at − 80 °C) was thawed and the volume size 
distribution of nanoparticles was immediately determined at 633 nm (Zetasizer Nano ZS, 
Malvern Instruments Limited). Far-UV circular dichroism (CD) was determined at 25 ºC in a 
Jasco J-715 spectropolarimeter to assess the secondary structure of T22-mRTA-H6, which 
was dissolved at 0.35 mg/ml in 166 mM sodium bicarbonate buffer, pH 8. The CD spectra 




scan rate of 50 nm/min, a response of 1 s and a band-with of 1 nm. Six scans were 
accumulated. The magnitude of secondary structure was analyzed using the JASCO spectra-
manager analysis software. To investigate potential intermolecular β-sheet structure in the 
protein nanoparticles, conventional methods for Thioflavin T (ThT) staining were adapted. 
Briefly, protein aliquots (10 µl) were added to 90 µl of 50 µM (Sigma Aldrich) in phosphate 
buffered saline (PBS), pH 7,4 and stirred for 1 min. The final protein concentration was 0.17 
mg/ml. ThT was excited at 450 nm and the fluorescence emission spectra was recorded in the 
range of 460 to 565 nm with a Varian Cary Eclipse spectrofluorimeter. The cross- β-sheet 
structure was monitored by the enhancement of the free dye fluorescence emission.  
 
5.6 Cell culture and determination of cell viability and apoptosis 
HeLa cells (ATCC-CCL-2) were cultured at 37 ºC in a 5% CO2 humidified atmosphere in 
MEM-Alpha media supplemented with 10% fetal calf serum (Gibco Thermo Fisher Scientific 
(TFS)). They were seeded in an opaque 96-well plate (3x104 cells/well) for 24 h. When 
insoluble T22-mRTA-H6 was assayed, the media was supplemented with 2% penicillin, 
10,000 U/ml streptomycin (Gibco, TFS). The next day soluble T22-mRTA-H6 was added and 
cells were exposed for 24, 48 and 72 h). Cells were also exposed to insoluble protein version 
during 24, 48, 72, 96, 120, and 144 h. Cell viability was determined by CellTiterGlo 
Luminescent Cell Viability Assay (Promega) in a Multilabel Plater Reader Victor3 (Perkin 
Elmer). For the CXCR4 specificity assay, the CXCR4 antagonist AMD3100 [33] was added 
at 10:1 molar ratio 1 h before the incorporation of the protein. Antagonist and protein were 
incubated in a final volume of 10 µl that were mixed with 90 µl of culture media. All soluble 
protein experiments were done in triplicate and insoluble protein with six replicates. 
On the other hand, the AML cell lines THP1 (ACC-16) and MV411 (ACC-102), as well as 
3T3 mouse fibroblasts (ACC-173), were purchased from DSMZ (Leibniz Institute DSMZ-
German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany). THP1 
was cultured in RPMI-1640 medium supplemented with 10% FBS, 10 mmol/l L-glutamine 
100 U/ml penicillin, 10 mg/ml streptomycin and 0.45 µg/ml fungizone. (Gibco, TFS). 3T3 
cells were cultured with DMEM medium adding the same supplements. Cells were kept at 
37°C in a humidified atmosphere of 5% CO2. Cell viability assays with these cell lines were 
performed using the XTT Cell Viability Kit II (Roche Diagnostics) and absorbance was read 
in a spectrophotometer at 490nm (BMG Labtech). The effect of the caspase inhibitor zVAD-




fmk) and then exposing them to 100 nM T22-mRTA-H6 for 48 hours. The antitumor drug 
Ara-C (Cytosine β-D-arabinofuranoside hydrochloride) was purchased from Sigma Aldrich. 
To allow the follow-up of AML in mice, THP1 AML cell line was transfected with a plasmid 
encoding the luciferase gene that confers bioluminescence that can be non-invasively imaged 
(BLI) to the cells. Briefly, THP1 cells were harvested in 24-well plates, treated with 0.5 µg of 
DNA plasmid and mixed with Lipofectamine LTX and PLUS reagents (A12621, Invitrogen, 
TFS) in Opti-MEM Reduced Serum Medium (Gibco, TFS) according to the manufacturer's 
instructions. 48 hours later BLI levels were tested incubating cells with luciferin in an IVIS 
Spectrum In Vivo Imaging System (PerkinElmer, Waltham, MA, USA). Finally, transfected 
cells were selected with 1.5 mg/mL geneticin (G418 Sulfate, Gibco, TFS) and BLI was 
analyzed periodically to check the preservation of the plasmid in cells, called THP1-Luci cells. 
Internalization of T22-GFP-H6 [30] in 3T3, MV411, THP1 and HeLa was determined by 
Fluorescence-activated cell sorting (FACS Calibur, BD). Cells were exposed for 1 hour to  
T22-GFP-H6 at 100 nM. Then, cells were washed with PBS and trypsinized (1 mg/ml trypsin, 
Life Technologies) in order to remove nonspecific binding of nanoparticles to the cell 
membrane. Finally, levels of intracellular GFP fluorescence were quantified by flow 
cytometry. Mean fluorescence intensity ratios are given as mean fluorescence intensity of the 
treated samples divided by the mean fluorescence intensity of the vehicles. 
To evaluate cell apoptosis, we performed nuclear staining with the Hoescht 3342 dye (Sigma- 
Aldrich) in HeLa cells exposed to 100 nM T22-mRTA-H6 or buffer for different times. Once 
the incubation was finished, the media was collected and centrifuged to obtain the suspended 
cells. They were rinsed with PBS and centrifuged again. The adhered cells were trypsinized 
and pulled together with those previously obtained. These cells were fixed (3.7 % p-
formaldehyde in PBS, pH 7.4) for 10 min at -20ºC, washed with PBS and resuspended in 10 
µl of PBS. Finally, cells were mounted on a slide with ProLong™ Gold Antifade Mountant 
with DAPI and observed for the appearance of the nuclei under a fluorescence microscope. In 
addition, externalizad phosphatidylserine protein-exposed cells was detected by Annexin 
Annexin V Detection Kit (APC, eBioscience) while dead cells were spotted with propidium 
iodide (PI), according to supplier instructions. Cell internalization was monitored using 
ATTO-labelled protein as described elsewhere. [23]  
 




On the other hand, levels of cellular ROS were measured with the Cellular ROS Detection 
Assay Kit (Abcam). In brief, HeLa cells were exposed to 100 nM T22-mRTA-H6 (15 or 24 
hours) or buffer. Then, cells were washed and incubated with ROS Detection Solution for 1 
hour at 37ºC, in the dark, adding 100 µM Pyocyanin (1 hour) to the positive controls. 
Afterwards, levels of fluorescence were read with a microplate reader (BMG Labtech) at 
Ex=488nm and Em=520nm. Values were expressed as relative fluorescence units after 
subtracting the background fluorescence of blanks.  Finally, to measure mitochondrial 
membrane potential (∆ψm), we used a mitochondrial potential detection kit (BD MitoScreen, 
BD Biosciences) according to manufacturer’s instructions. Labelled cells were analyzed by 
flow cytometry and the data were expressed as percentage of cells containing depolarized 
mitochondria (loss of JC-1 red fluorescence). 
 
5.8 Flow cytometry 
CXCR4 membrane expression was determined by Fluorescence-activated cell sorting (FACS 
Calibur, BD). Cells were washed with PBS 0.5 % BSA and incubated either with PE-Cy5 
mouse anti-CXCR4 monoclonal antibody (BD Biosciences) or PE-Cy5 Mouse IdG2a isotype 
(BD Biosciences) as control. Results of fluorescence emission were analyzed with software 
Cell Quest Pro and expressed as the ratio between the mean fluorescence intensity of each 
sample and the isotype values. 
 
5.9 Electron microscopy 
The ultrastructure of soluble (in form of nanoparticles) and insoluble (in form of IBs) T22-
mRTA-H6 was observed by field emission scanning electron microscopy (FESEM). Insoluble 
protein was resuspended in PBS and sonicated at 10% amplitude 0.5 s ON/OFF for 1 min. 
Drops of 10 µL of either soluble protein in storage buffer or insoluble protein in PBS were 
deposited during 1 min on silicon wafers (Ted Pella), excess of liquid eliminated, and air 
dried. Samples without coating were observed with an in-lens detector in a FESEM Zeiss 
Merlin (Zeiss) operating at 1kV. Representative images were obtained at a wide range of 
magnifications (from 100,000x to 450,000x). 
 




NSG (NOD-scid IL2Rgammanull) female mice (5 weeks old) were obtained from Charles 
River Laboratories (Wilmington, MA, USA) and housed in microisolator units with sterile 
food and water ad libitum. After 1 week in quarantine, NSG mice were intravenously (IV) 
injected with luciferase-transfected THP1 cells (THP1-Luci; 1 x 106 cells/ 200 µL) and 
divided randomly into three different experimental groups. One group (VEHICLE; n=3) was 
IV injected with NaCO3H pH=8 buffer, a second group (T22mRTA; n=1) was administered 
with 10 µg of T22-mRTA-H6. Both groups were injected with a daily dose for a total of 10 
doses. A third group (IB-T22mRTA; n=2) was subcutaneously (SC) injected once with 1 mg 
of T22-mRTA-H6 IBs. These treatments started 2 days after the IV injection of THP1-Luci 
cells in mice, which generated the disseminated AML model. Evolution of AML 
dissemination was monitored in IVIS Spectrum three times per week until the day of the 
euthanasia. Weight of the animals was measured the same day of BLI analysis. All mice were 
euthanized the day that the first of them presented relevant signs of disease such as 10% 
weight loss or lack of mobility. Animals were intraperitoneally injected with luciferin, and 
after 5 min mice were killed by cervical dislocation. Tissues were excised and the BLI levels 
of the organs ex vivo analyzed. After that, they were preserved in formaldehyde 3.7% and 
paraffin embedded for further immunohistochemistry analyses. The analysis and detection of 
BLI was performed using radiance photons in Living Image 4.4 Software both in in vivo and 
ex vivo studies. All procedures were conducted in accordance with the guidelines approved by 
the institutional animal Ethics Committee of Hospital Sant Pau. 
 
5.11 Histopathology and immunohistochemical staining 
Sections of paraffin-embedded samples of infiltrated (liver, spleen, hindlimbs and backbone) 
and normal (lung, heart and kidney) organs were hematoxylin and eosin (H&E) stained and 
the presence of toxicity was analyzed. Moreover, in order to detect AML cells in infiltrated 
tissues, immunohistochemical analysis with anti-human CD45 antibody (DAKO) was done in 
paraffin-embedded tissue samples. Staining was performed in a Dako Autostainer Link 48, 
following the manufacturer’s instructions. Two independent observers evaluated all samples, 
using an Olympus BX51 microscope (Olympus). Images were acquired using an Olympus 
DP72 digital camera and processed with CellD Imaging 3.3 software (Olympus). 
 




Quantitative data are expressed as mean ± standard error (SE). Previously to perform 
statistical analyses, all variables were tested for normality and homogeneity of variances 
employing the Shapiro-Wilk and the Levene test, respectively. Comparisons of soluble 
protein cytotoxicity effects and competition assays were made with Tukey’s test. Meanwhile 
protein cytotoxicity assays were assessed by Mann-Whitney U tests. Significance was 
accepted at p<0.05. 
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